Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,038 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study).
Watanabe K, Hosomi Y, Naoki K, Nakahara Y, Tsukita Y, Matsumoto H, Yoh K, Fujisaka Y, Takahashi S, Takata S, Usui K, Kishi K, Naka G, Tamano S, Uemura K, Kunitoh H. Watanabe K, et al. Among authors: matsumoto h. JTO Clin Res Rep. 2024 Sep 7;5(11):100720. doi: 10.1016/j.jtocrr.2024.100720. eCollection 2024 Nov. JTO Clin Res Rep. 2024. PMID: 39416709 Free PMC article.
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: matsumoto h. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC.
Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Haratani K, Itoh S, Uemura T, Morinaga R, Takahama T, Nakashima K, Tachihara M, Saito G, Tanizaki J, Otsubo K, Ikeda S, Matsumoto H, Hara S, Hata A, Masuda T, Yamamoto N. Fujimoto D, et al. Among authors: matsumoto h. JTO Clin Res Rep. 2021 Dec 16;3(2):100265. doi: 10.1016/j.jtocrr.2021.100265. eCollection 2022 Feb. JTO Clin Res Rep. 2021. PMID: 35146460 Free PMC article.
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: matsumoto h. Chest. 2022 Nov;162(5):1188-1198. doi: 10.1016/j.chest.2022.05.035. Epub 2022 Jun 1. Chest. 2022. PMID: 35661746
First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan.
Goto Y, Tamura A, Matsumoto H, Isobe K, Ozaki T, Santorelli ML, Taniguchi K, Kamitani T, Irisawa M, Kanda K, Abe M, Burke T, Nokihara H. Goto Y, et al. Among authors: matsumoto h. JTO Clin Res Rep. 2022 Aug 5;3(9):100397. doi: 10.1016/j.jtocrr.2022.100397. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36065450 Free PMC article.
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.
Imaji M, Fujimoto D, Sato Y, Sakata Y, Oya Y, Tamiya M, Suzuki H, Ikeda H, Kijima T, Matsumoto H, Kanazu M, Hino A, Inaba M, Tsukita Y, Arai D, Maruyama H, Hara S, Tsumura S, Kobe H, Sumikawa H, Sakata S, Yamamoto N. Imaji M, et al. Among authors: matsumoto h. Eur J Cancer. 2023 Jan;179:15-24. doi: 10.1016/j.ejca.2022.10.029. Epub 2022 Nov 12. Eur J Cancer. 2023. PMID: 36470023
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: matsumoto h. Lung Cancer. 2023 Dec;186:107426. doi: 10.1016/j.lungcan.2023.107426. Epub 2023 Nov 19. Lung Cancer. 2023. PMID: 37992594
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).
Kawachi H, Tamiya M, Oya Y, Saito G, Taniguchi Y, Matsumoto H, Sato Y, Otsuki T, Suzuki H, Fukuda Y, Tanaka S, Tsukita Y, Uchida J, Sakata Y, Nakatani Y, Shibaki R, Arai D, Okada A, Hara S, Takayama K, Nishino K. Kawachi H, et al. Among authors: matsumoto h. Clin Lung Cancer. 2024 Nov;25(7):643-652.e4. doi: 10.1016/j.cllc.2024.07.014. Epub 2024 Jul 25. Clin Lung Cancer. 2024. PMID: 39138106
Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: matsumoto h. Lung Cancer. 2024 Feb;188:107450. doi: 10.1016/j.lungcan.2023.107450. Epub 2023 Dec 30. Lung Cancer. 2024. PMID: 38160082 No abstract available.
Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study.
Sato Y, Fujiwara S, Hata A, Kida Y, Masuda T, Amimoto H, Matsumoto H, Miyoshi K, Otsuka K, Tomii K. Sato Y, et al. Among authors: matsumoto h. JTO Clin Res Rep. 2023 Nov 19;4(12):100608. doi: 10.1016/j.jtocrr.2023.100608. eCollection 2023 Dec. JTO Clin Res Rep. 2023. PMID: 38162177 Free PMC article.
5,038 results